- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02673177
Trial of Robotic Versus Laparoscopic-assisted Radical Resection for Rectal Cancer (TRVL)
February 2, 2016 updated by: Tang Bo, Southwest Hospital, China
A Randomized, Prospective Trial of Robotic Versus Laparoscopic-assisted Radical Resection for Rectal Cancer in Urinary, Erectile Function and Anal Function
This study compared robot-assisted total mesorectal excision (RTME) and laparoscopic total mesorectal excision (LTME) with regard to urinary function, sexual function and sphincter- preservation outcomes for low rectal cancer.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Urinary and sexual dysfunction are recognized complications of rectal cancer surgery in men.
This study compared robot-assisted total mesorectal excision (RTME) and laparoscopic total mesorectal excision(LTME) with regard to these functional outcomes.Sphincter- preservation outcomes for low rectal cancer was observed as well.
Study Type
Interventional
Enrollment (Anticipated)
225
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 1. Patients who are acceptable to two surgical procedures for the robot- assisted or laparoscopy-assisted rectal cancer, are willing to randomized trial;
- 2. Matching the diagnostic criteria;
- 3. Aged 18-70 years old;
- 4. Preoperative TNM staging (CT, laparoscopic exploration): cT1-3N0-3M0 (excluding M1, T4);
- 5. Preoperative ASA 3 scores;
- 6. There was no history of malignancy, no other malignant tumors by preoperative examination;
- 7. Without undergoing definitive treatment, such as radiotherapy, chemotherapy or immunotherapy preoperatively;
- 8. The informed consent form was signed by the patient himself(herself)or his principal agent;
- 9. In accordance with the international erectile function questionnaire (IIEF) urinary function scale, The urinary sexual function are normal.
Exclusion Criteria:
- 1. Age less than 18 years old or more than 70 years old;
- 2. Previous psychiatric patients or patients refused to sign the informed consent;
- 3. Attending other related clinical studies on surgical treatment of rectal cancer;
- 4. The patient has a history of malignant tumor, or a combination of other malignant tumors;
- 5. Patients have been treated with definitive treatment: radiotherapy, chemotherapy or immunotherapy;
- 6. Patients had received otherper abdominal operations (except for laparoscopic cholecystectomy);
- 7. ASA >3;
- 8. Laparoscopic surgical contraindications: such as severe heart lung disease; abdominal wall hernia; diaphragmatic hernia; coagulation disorder; portal hypertension; pregnancy, etc.;
- 9. Those who has been confirmed to be unable to do a radical resection (T4 stage) for local advanced tumor;
- 10. Those who have urination sexual dysfunction preoperatively.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Robot-assisted total mesorectal excision
Robot-assisted total mesorectal excision (RTME) for rectal cancer.
Two different RTME procedures were chose to personalized patients.
Generally, when the tumor located within 5-15cm from the anal verge, low anterior resection (LAR) was employed, and tumor located below 5cm, abdominoperineal resection (APR) was applied usually.
|
The Da Vinci Surgical System may help to protect subtle anatomical structure and provide more functional protection when compared to laparoscopic surgery.
This study aimed to compare RTME and laparoscopic total mesorectal excision (LTME) for rectal cancer with regard to Urinary, sexual function and sphincter- preservation outcomes.
|
Active Comparator: Laparoscopic total mesorectal excision
Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer was performed.
The Urinary, sexual function and sphincter- preservation outcomes were evaluated.
|
Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of sexual and urinary dysfunction
Time Frame: One years after surgery
|
One years after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
disease-free survival(DFS )
Time Frame: 3 years disease-free survival
|
DFS was defined as from the date of randomization to the date of tumor recurrence or death from any cause
|
3 years disease-free survival
|
Anus preservation rate
Time Frame: One years after surgery
|
One years after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2016
Primary Completion (Anticipated)
May 1, 2018
Study Completion (Anticipated)
May 1, 2019
Study Registration Dates
First Submitted
January 27, 2016
First Submitted That Met QC Criteria
February 1, 2016
First Posted (Estimate)
February 3, 2016
Study Record Updates
Last Update Posted (Estimate)
February 4, 2016
Last Update Submitted That Met QC Criteria
February 2, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015(43)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Neoplasms
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
SafeHeal IncSuspendedSafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study (SAFE-2)Colorectal Cancer | Rectal Cancer | Rectal Tumor | Rectal/AnalUnited States, France, Belgium
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage II Rectal Cancer AJCC v8 | Locally Advanced Rectal CarcinomaUnited States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
National Cancer Institute (NCI)CompletedRectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage II Rectal Cancer AJCC v7United States
-
National Cancer Institute (NCI)NRG OncologyCompletedRectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage II Rectal Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
-
First Affiliated Hospital of Guangxi Medical UniversityRecruitingRectal Cancer | Rectal Cancer Stage II | Rectal Cancer Stage IIIChina
Clinical Trials on robot-assisted total mesorectal excision
-
Third Military Medical UniversityCompletedRectal Cancer | Perioperative ComplicationChina
-
The First Hospital of Jilin UniversityJilin Provincial Tumor Hospital; Daping Hospital and the Research Institute... and other collaboratorsNot yet recruitingRectal Neoplasms | Laparoscopy | Robotic Surgical Procedures | Total Mesorectal ExcisionChina
-
University Hospital Gregorio MarañónHospital del Río Hortega; Hospital de Leon; University of Navarrra Hospital (Clinica...RecruitingRectal Cancer | Sphincter Ani IncontinenceSpain
-
Sun Yat-sen UniversityCompleted
-
National Cancer Center, KoreaActive, not recruitingRectal CancerKorea, Republic of
-
Yanhong DengCompleted
-
Ruijin HospitalWithdrawn
-
Sun Yat-sen UniversityRecruiting
-
Cantonal Hospital of St. GallenRecruitingRecurrence | Mortality | Survival | Postoperative MorbiditySwitzerland
-
Case Comprehensive Cancer CenterRecruitingRectal CancerUnited States